Litigation Details for Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)

Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)

Docket		Date Filed	2017-07-13
Court	District Court, D. Delaware	Date Terminated	2019-11-14
Cause	35:271 Patent Infringement	Assigned To	Joseph F. Bataillon
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	9,119,876; 9,295,657
Link to Docket	External link to docket

Details for Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2017-07-13	1	Complaint	U.S. Patent No. 9,119,876 (“the ’876 patent”) and U.S. Patent No. 9,295,657 (“the ’657 patent”) (collectively…collectively, the “Patents-in-Suit”) pursuant to the Patent Laws of the United States, 35 U.S.C. § 1, … THE PATENTS-IN-SUIT 9. The ’876 patent, titled “Epinephrine Formulations… of the ’876 patent is attached hereto as Exhibit A. 11. The ’657 patent, titled “Epinephrine…Par obtained the ’876 and ’657 patents. 21. The ’876 patent covers the technological advance	External link to document
2018-11-15	120	Notice of Service	Amended Invalidity Contentions on U.S. Patent Nos. 9,119,876 and 9,295,657 filed by Hospira, Inc..(Haney… 14 November 2019 1:17-cv-00944 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-06-04	189	Memorandum and Order	expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…,657 (“the ’657 patent”) (together, “the Patents-in-Suit”) (Exs. 1-2). Par contends that Hospira’s ANDA…contention that if a patent describes only a single embodiment, the claims of the patent must be construed…112 of the Patent Act requires that the claims themselves set forth the limits of the patent grant, but… ANDA Product infringes the Patents-in-Suit under 35 U.S.C. § 271(e)(2), and that the manufacture, use	External link to document
2019-06-04	190	Memorandum and Order	expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…9,295,657 (“the ’657 patent”) (together, “the Patents-in- Suit”) (D.I. 1, Exs. 1-2). The patents-in-suit are …letter request for sanctions (D.I. 124). This is a patent infringement case arising under the Hatch-Waxman…the conditions specified by claims 12-19 of the patents-in-suit.” D.I. 54. While the parties were… 14 November 2019 1:17-cv-00944 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-06-06	191	Memorandum and Order	expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…,657 (“the ’657 patent”) (together, “the Patents-in-Suit”) (D.I. 1, Exs. 1- 2). Par alleges that Hospira…509 U.S. 579, 597 (1993) (D.I. 149).1 This is a patent infringement case arising under the Hatch-Waxman…Hospira’s ANDA Product infringes the Patents-in-Suit under 35 1 Also pending is a request for oral argument…importation of Hospira’s ANDA Product will infringe the Patents-in-Suit under 35 U.S.C. §§ 271(a), (b), and/or	External link to document
2019-06-21	197	Memorandum and Order	expiration of the patents-in-suit. In its complaint, Par Pharma alleges infringement of U.S. Patent Nos. 9,119,876…9,119,876 (“the ‘'876 patent”) and 9,295,657 (“the ‘'''657 patent") (together, the… four additional patent applications claiming priority to one of the asserted patents to show that “the…Claim Term “About.” D.I. 193. This is an action for patent infringement under the Hatch-Waxman Act, 21 U.…the "patents-in-suit"). The parties agreed to construe the term “about” as having its	External link to document